Trial Profile
A Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys with Duchenne Muscular Dystrophy
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 10 Jan 2024
Price :
$35
*
At a glance
- Drugs Talditercept alfa (Primary)
- Indications Duchenne muscular dystrophy
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb; Chugai Pharmaceutical; Roche
- 08 Jan 2024 Results from NCT02515669 and NCT03039686 , published in the Neurology and Therapy
- 25 Nov 2020 Status changed from discontinued to completed.
- 24 Jul 2020 This trial has been completed in France,according to European Clinical Trials Database record.